FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:908-917 March 6, 2003 Number 10 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Lee, M. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Treatment with a luteinizing hormone–releasing hormone (LHRH) agonist increases adult height in children with LHRH-dependent precocious puberty and is prescribed by some practitioners to augment height in short adolescents. We performed a randomized clinical trial to determine whether treatment with an LHRH agonist increases adult height in short adolescents with normally timed puberty.

Methods Fifty short adolescents (18 boys and 32 girls) with low predicted adult height (mean [±SD], 3.3±1.2 SD below the population mean) received either placebo (24 subjects) or an LHRH agonist (26 subjects). The mean (±SD) duration of treatment was 3.5±0.9 years in the LHRH-agonist group and 2.1±1.2 years in the placebo group (P<0.001). Adult height was measured when bone age exceeded 16 years in girls and 17 years in boys and when the rate of growth was less than 1.5 cm per year.

Results Forty-seven adolescents (94 percent) were followed until they attained adult height. At the time adult height was achieved, the subjects who had been treated with an LHRH agonist were older than those who had received placebo (20.5±2.1 years vs. 18.0±2.5 years, P=0.01) and were taller (standard-deviation score, –2.2±1.1 vs. –3.0±1.2; P=0.01). Analysis of covariance showed that LHRH-agonist treatment resulted in an increase of 0.6 (95 percent confidence interval, 0.2 to 0.9) in the standard-deviation score for height, or an increase of 4.2 cm (95 percent confidence interval, 1.7 to 6.7), over the initially predicted adult height (P=0.01). Treatment with an LHRH agonist resulted in significantly greater adult height than did placebo in boys and girls, in adolescents with idiopathic short stature, and in those who had a growth-limiting syndrome. The principal adverse event in the LHRH-agonist group was decreased accretion of bone mineral density (mean lumbar vertebral bone mineral density at the time adult height was achieved, 1.6±1.2 SD below the population mean, vs. 0.3±1.2 SD below the population mean in the placebo group; P<0.001).

Conclusions Treatment with an LHRH agonist for 3.5 years increases adult height by 0.6 SD in adolescents with very short stature but substantially decreases bone mineral density. Such treatment cannot be routinely recommended to augment height in adolescents with normally timed puberty.

Source Information

From the Unit on Growth and Obesity (J.A.Y.) and the Section on Developmental Endocrinology (J.A.Y., S.R.R., G.M., O.H.P., F.G.C., G.B.C.), Developmental Endocrinology Branch, National Institute of Child Health and Human Development, and the Diagnostic Radiology Division, Warren Grant Magnuson Clinical Center (S.C.H.), National Institutes of Health, Bethesda, Md.

Address reprint requests to Dr. Yanovski at the National Institutes of Health, 10 Center Dr., Bldg. 10, Rm. 10N262, MSC 1862, Bethesda, MD 20892-1862, or at yanovskj{at}mail.nih.gov.

Full Text of this Article

Related Letters:

Is Luteinizing Hormone–Releasing Hormone Agonist Justified in Short Adolescents?
Taback S. P., Sellers E. A.C., Dean H. J., Lee M. M.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:192-193, Jul 10, 2003. Correspondence

This article has been cited by other articles:

• Carel, J.-C., Eugster, E. A., Rogol, A., Ghizzoni, L., Palmert, M. R., on behalf of the members of the ESPE-LWPES GnRH An, (2009). Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children. Pediatrics 123: e752-e762 [Abstract] [Full Text]  
• Cohen, P., Rogol, A. D., Deal, C. L., Saenger, P., Reiter, E. O., Ross, J. L., Chernausek, S. D., Savage, M. O., Wit, J. M., on behalf of the 2007 ISS Consensus Workshop parti, (2008). Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J. Clin. Endocrinol. Metab. 93: 4210-4217 [Abstract] [Full Text]  
• Shulman, D. I., Francis, G. L., Palmert, M. R., Eugster, E. A., for the Lawson Wilkins Pediatric Endocrine Society, (2008). Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development. Pediatrics 121: e975-e983 [Abstract] [Full Text]  
• van Gool, S. A., Kamp, G. A., Visser-van Balen, H., Mul, D., Waelkens, J. J. J., Jansen, M., Verhoeven-Wind, L., Delemarre-van de Waal, H. A., de Muinck Keizer-Schrama, S. M. P. F., Leusink, G., Roos, J. C., Wit, J. M. (2007). Final Height Outcome after Three Years of Growth Hormone and Gonadotropin-Releasing Hormone Agonist Treatment in Short Adolescents with Relatively Early Puberty. J. Clin. Endocrinol. Metab. 92: 1402-1408 [Abstract] [Full Text]  
• Bonjour, J.-P., Chevalley, T. (2007). Pubertal Timing, Peak Bone Mass and Fragility Fracture Risk. IBMS BoneKEy 4: 30-48 [Abstract] [Full Text]  
• Maghnie, M., Ambrosini, L., Cappa, M., Pozzobon, G., Ghizzoni, L., Ubertini, M. G., di Iorgi, N., Tinelli, C., Pilia, S., Chiumello, G., Lorini, R., Loche, S. (2006). Adult Height in Patients with Permanent Growth Hormone Deficiency with and without Multiple Pituitary Hormone Deficiencies. J. Clin. Endocrinol. Metab. 91: 2900-2905 [Abstract] [Full Text]  
• Carel, J.-C., Elie, C., Ecosse, E., Tauber, M., Leger, J., Cabrol, S., Nicolino, M., Brauner, R., Chaussain, J.-L., Coste, J. (2006). Self-Esteem and Social Adjustment in Young Women with Turner Syndrome--Influence of Pubertal Management and Sexuality: Population-Based Cohort Study. J. Clin. Endocrinol. Metab. 91: 2972-2979 [Abstract] [Full Text]  
• Foster, C. M. (2006). Does lupron dosage make a difference in outcome when treating children with precocious puberty?. J. Clin. Endocrinol. Metab. 91: 1667-1668 [Full Text]  
• Zhou, P., Shah, B., Prasad, K., David, R. (2005). Letrozole Significantly Improves Growth Potential in a Pubertal Boy With Growth Hormone Deficiency. Pediatrics 115: e245-e248 [Abstract] [Full Text]  
• Brownstein, C. M., Mertens, A. C., Mitby, P. A., Stovall, M., Qin, J., Heller, G., Robison, L. L., Sklar, C. A. (2004). Factors That Affect Final Height and Change in Height Standard Deviation Scores in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study. J. Clin. Endocrinol. Metab. 89: 4422-4427 [Abstract] [Full Text]  
• Carel, J.-C., Lahlou, N., Roger, M., Chaussain, J. L. (2004). Precocious puberty and statural growth. Hum Reprod Update 10: 135-147 [Abstract] [Full Text]  
• Faustini-Fustini, M., Balestrieri, A., Rochira, V., Carani, C. (2003). The Apparent Paradox of Tall Stature with Hypopituitarism: New Insights from an Old Story. J. Clin. Endocrinol. Metab. 88: 4002-4003 [Full Text]  
• Taback, S. P., Sellers, E. A.C., Dean, H. J., Lee, M. M. (2003). Is Luteinizing Hormone-Releasing Hormone Agonist Justified in Short Adolescents?. NEJM 349: 192-193 [Full Text]  
• Lee, M. M. (2003). Is Treatment with a Luteinizing Hormone-Releasing Hormone Agonist Justified in Short Adolescents?. NEJM 348: 942-945 [Full Text]